Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Prostate Health market size is expected to hit around USD 55.9 billion by 2030 from valued at USD 31.9 billion in 2021 and growing at a CAGR of 10.4% from 2022 to 2030.

The prostate gland (the prostate) is an organ of the male reproductive system. The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer. Benign prostatic hyperplasia (BPH) is defined as a medical condition affecting men. It involves the non-cancerous enlargement of the prostate gland. While BPH rarely shows symptoms before the age of 40, the risk of contracting BPH increases with age. The condition affects nearly 50% of men between the ages of 51 and 60 and up to 90% of men older than 80. Treatment measures such as medications and surgery have been used for patients with BPH.

 Report Scope of the Prostate Health Market

COVID-19 Impact on the Prostate Health Market

The prostate health market witnessed a loss of business, and the trend continued till late December 2020. Unfavorable changes in regulations and guidelines are hampering the growth of this industry. Major regulatory authorities across the globe (such as CDC, WHO, MHRA, TGA, and EMA) have identified that cancer patients are at greater risk of COVID-19 infection than healthy adults. Thus, screening, diagnostic exams, and surgical procedures are severely restricted or postponed at hospitals and cancer care centers. This is expected to cause disruptions in the prostate health market. Owing to the factors above, caregivers and hospitals are expected to witness delays in elective surgeries and screening procedures. However, the market has gradually risen from the second half of 2020 due to the increase in the number of oncology appointments, prostate cancer therapies among others resulting from efforts to clear backlogs and new cases and fully re-opened healthcare services.

Drivers: Growing prevalence of prostate cancer and BPH

The growth in the market is majorly driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in BPH treatment, rising prevalence of prostate cancer, increasing demand for hormone therapy drugs, emerging therapies for prostate cancer, and the increasing incidence of prostatitis. Data from the Health Insurance Review and Assessment (HIRA) agency in 2018 revealed that nearly 7,600,000 patients were diagnosed with BPH in 2010, which increased by ~1.2 million in 2017. This represents an annual increase of about 7% and a total increase of 58% from 2010. Obesity and BPH are closely associated. Obesity leads to several mechanisms such as increased sympathetic nervous activity, altered endocrine status, increased intra-abdominal pressure, increased inflammation process, and oxidative stress, which are favorable conditions for the development of BPH. The incidence of prostate cancer increases with an increase in age. Prostate cancer is the most common type of cancer among men. According to the American Cancer Society’s estimates for prostate cancer in 2021, about 248,530 new cases and 34,130 deaths occurred in 2020 due to prostate cancer in the US. The prostate cancer phase III pipeline is diverse and includes molecules in approved drug classes as well as drugs with novel mechanisms of action, including radioligands targeted to prostate-specific membrane antigen (PSMA), kinase inhibitors, and immune checkpoint inhibitors.

Restraints: Side effects associated with BPH medications

While drugs and surgery can treat BPH, both methods are associated with significant side effects. Medicines commonly used to treat BPH include alpha blockers, 5-ARIs (5-alpha reductase inhibitors), and other drug classes. Common side effects of alpha blockers include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Dizziness and orthostatic hypotension are of increased concern among the elderly as they can cause significant morbidities such as falls and subsequent injuries.

Finasteride and Dutasteride (among other 5-ARIs) convert testosterone to dihydrotestosterone. These drugs also reduce the synthesis of several neuroactive steroids, but the modulation of the neuroendocrine stress response may lead to depression. Other side effects of 5-ARIs are gynecomastia, impotence, and decreased libido and ejaculate volume.

Opportunities: Emerging Economics

Emerging economies (such as China, India, Brazil, and Mexico) are expected to offer significant growth opportunities to market players in the coming years. Factors such as the presence of a large target patient population, rising healthcare expenditure, growing awareness among physicians, and significant growth in the geriatric population are expected to boost the demand for prostate health methods across these countries.

The Asia Pacific is home to a large and rapidly growing patient population for benign prostatic hyperplasia. Moreover, the proportion of geriatric individuals (who are at a higher risk for these target indications) in the overall population is expected to increase sharply in the region, especially in Japan, China, South Korea, Hong Kong, and Taiwan (Source: US Census Bureau). Considering these factors, prominent and emerging product manufacturers in the prostate health market are increasingly focusing on expanding their businesses across emerging Asia Pacific countries.

Challenges: Low awareness regarding prostate health among men

BPH is mostly mistaken as an untreatable part of aging rather than a condition that can be treated by visiting the urologist’s office. The lack of awareness about the signs and symptoms of BPH may lead to many men being left undiagnosed, which may further increase the damage caused to the prostate.

North America holds the largest share in this market

North America has been among the frontrunners in developing prostate health therapies in the healthcare industry. The market growth in the US (a major contributor to the North American prostate health market) can be mainly attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong healthcare infrastructure, research funding, and product launches have accelerated the growth of this market.

Recent Developments

• In October 2020, Israeli medical device manufacturer Butterfly Medical raised USD 7 million in a Series B round to develop an anatomically shaped nitinol implant positioned in the prostatic urethra to relieve BPH symptoms
• In February 2018, California-based medical device startup, Zenflow, announced a USD 31.4-million Series A financing round to continue its minimally invasive approach to treating BPH. Its solution is a device to prop open the urethra, thereby treating the symptoms of BPH without the need for surgery or medications.
• In July 2019, Israel-based ProArc Medical received a USD 2.2-million grant from the Horizon 2020 program as a part of the European Innovation Council pilot. The two-year grant supports scientific studies and the commercialization of ProArc’s ClearRing BPH implant.
• In 2020, Asahi Kasei Pharma obtained drug approval in China for Flivas (naftopidil), an agent for treating dysuria associated with BPH.
• In 2018, NeoTract, a Teleflex subsidiary, received Japanese regulatory approval for the UroLift System to treat enlarged prostate. The company estimated that about 2.3 million men aged 50 and older in Japan were diagnosed with BPH.

Some of the prominent players in the Prostate Health Market include:

Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Prostate Health market

By Disease Indication

• Prostate Cancer
• AR Directed Therapies
• Hormone ADT
• Cytotoxic Agents
• PARP Inhibitors
• Others
• Benign Prostate Hyperplasia
• Alpha Blockers
• Alfuzosin
• Doxazosin
• Tamsulosin
• Silodosin
• Other Alpha Blockers
• 5 Alpha Reductase
• Finasteride
• Dutasteride
• Others
• Prostatitis
• Prescription
• Over the counter

By Regional Outlook

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Prostate Health industry analysis from 2022 to 2030 to identify the prevailing Prostate Health industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Prostate Health industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Prostate Health industry trends, key players, market segments, application areas, and market growth strategies.